Katherine Blesie
Why sickle cell disease is a perfect target candidate for CRISPR gene editing
When the gene-editing technology CRISPR/Cas9 was discovered in 2012 by Berkeley biochemist Jennifer Doudna and collaborator Emmanuelle Charpentier, it changed ...
